Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
Why AbbVie Expects Rova-T to Earn so Big in Peak Sales
Marketwatch
Sun, 07/10/16 - 12:07 pm
AbbVie
Rova-T
Stemcentrx
lung cancer
Biogen, AbbVie: How Significant is the New MS Drug Zinbryta
Bidness, ETC
Wed, 07/6/16 - 10:54 am
Biogen
AbbVie
Zinbryta
MS
multiple sclerosis
Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
Market Realist
Wed, 07/6/16 - 09:48 am
AbbVie
Imbruvica
diffuse large B-cell lymphoma
Generics giant Teva join PhRMA? AbbVie, others aren't having it
Fierce Pharma
Tue, 07/5/16 - 10:00 pm
generics
Teva Pharmaceutical
AbbVie
PhRMA
Biotech: What's Ahead For The Second Half Of 2016
Seeking Alpha
Tue, 07/5/16 - 09:57 am
biotech
AbbVie
Amgen
Allergan
Anacor
Gilead Sciences
Medivation
Pfizer
Sanofi
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Sat, 07/2/16 - 12:36 pm
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AstraZeneca
Lynparza
Medivation
AbbVie
Clovis Oncology
Understanding Trinity: Inside the Testing of AbbVie’s Rova-T
Marketwatch
Fri, 07/1/16 - 12:15 pm
AbbVie
Rova-T
small cell lung cancer
AbbVie Inc Bags Fourth Breakthrough Therapy Status for Imbruvica
Bidness, ETC
Thu, 06/30/16 - 09:35 am
AbbVie
breakthrough therapies
Imbruvica
cGVHD
graft vs host disease
6 Biopharma Movers Making a Run on Wednesday
24/7 Wall St
Wed, 06/15/16 - 05:50 pm
Aegerion
Cellectar
Infinity Pharma
AbbVie
QLT
AbbVie's Rova-T Update at ASCO: Good or Bad?
Motley Fool
Sun, 06/12/16 - 09:54 pm
AbbVie
Rova-T
ASCO 2016
small cell lung cancer
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
Fri, 06/10/16 - 04:16 pm
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
What AbbVie Bought for $5.8 Billion
Motley Fool
Mon, 06/6/16 - 11:25 am
AbbVie
Stemcentrx
M&A
Rova-T
lung cancer
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Yahoo
Mon, 06/6/16 - 11:23 am
AbbVie
Imbruvica
CLL
small lymphocytic lymphoma
ASCO 2016
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Yahoo
Sun, 06/5/16 - 12:03 pm
AbbVie
glioblastoma
brain cancer
ASCO 2016
ABT-414
AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors
Forbes
Sun, 06/5/16 - 11:50 am
AbbVie
Rova-T
non-small cell lung cancer
ASCO 2016
AbbVie: Not Its First Rodeo
Seeking Alpha
Fri, 06/3/16 - 09:52 am
AbbVie
Humira
patents
3 Stories To Watch At The Year’s Biggest Cancer Conference
Investors.com
Mon, 05/30/16 - 06:34 pm
ASCO 2016
Pfizer
Eli Lilly
breast cancer
Ibrance
abemaciclib
AbbVie
non-small cell lung cancer
Rova-T
Keytruda
Bristol-Myers Squibb
Merck
Opdivo
Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline
Motley Fool
Mon, 05/30/16 - 10:13 am
JNJ
Pfizer
Novartis
Merck
Bristol-Myers Squibb
GSK
Sanofi
AbbVie
Eli Lilly
AstraZeneca
How Do Allergan’s Valuations Compare to Its Peers’?
Yahoo/Market Realist
Sat, 05/28/16 - 10:49 am
Allergan
AbbVie
Pfizer
Merck
Biogen, AbbVie once-monthly MS injection wins U.S. approval
Yahoo/Reuters
Fri, 05/27/16 - 11:03 pm
Biogen
AbbVie
MS
multiple sclerosis
FDA
Zinbryta
Pages
« first
‹ previous
…
46
47
48
49
50
51
52
53
54
…
next ›
last »